Literature DB >> 30535975

Central compartment revision surgery for persistent or recurrent thyroid carcinoma: analysis of survival and complication rate.

Gabriele Molteni1, Marco Bonali2, Francesco Mattioli2, Michael Ghirelli3, Matteo Fermi2, Gaetano Ferri2, Malagoli Andrea4, Livio Presutti2.   

Abstract

PURPOSE: Locoregional recurrence of thyroid carcinoma is relatively common and reported rate are between 5 and 20%. Cervical nodes are usually involved, especially at the central compartment. The management of recurrent thyroid carcinoma at central compartment still remains challenging because of higher incidence of complication rate. The aim of the study is to evaluate the survival and complications rate after revision surgery.
METHODS: Retrospective cohort study on a group of patients that underwent revision surgery for persistent or recurrent thyroid carcinoma from January 1, 2003 to December 31, 2017. Survival outcomes were calculated using Kaplan-Meier method. Significant variables on univariate analysis were subjected to a Cox proportional hazards regression multivariate model.
RESULTS: Fifty-two patients involved, 22 male (40%) and 30 female (60%). Mean age was 54 years old (range 24-85). Mean follow-up was 79 months, median follow-up was 85 months, with a range between 8 and 153 months. The 5-year overall survival was 90.8% while at 10 years it was 69.8%. The 5-year disease-specific survival was 93.5%, while at 10 years it dropped to 77.9%. The rate of recurrent laryngeal nerve paralysis and persistent hypocalcemia in our series were 1.3% and 5.9%, respectively. No evidence of thoracic duct, esophageal or laryngeal and tracheal injury was found in this case series. Regarding prognostic factors, univariate and multivariate analysis highlighted as statistically significant: the aggressive histological variants, the presence extranodal extension or soft-tissue metastasis.
CONCLUSION: The surgical option remains the gold standard in locoregional recurrences of thyroid carcinoma and should be performed by experienced surgeons to reduce postoperative complications.

Entities:  

Keywords:  Central compartment; Complications; Hypocalcemia; Neck dissection; Nodal metastases; Thyroid cancer; Vocal fold palsy

Mesh:

Year:  2018        PMID: 30535975     DOI: 10.1007/s00405-018-5239-2

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  28 in total

1.  Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma.

Authors:  M Schlumberger; C Challeton; F De Vathaire; J P Travagli; P Gardet; J D Lumbroso; C Francese; F Fontaine; M Ricard; C Parmentier
Journal:  J Nucl Med       Date:  1996-04       Impact factor: 10.057

2.  Therapy of unilateral vocal fold paralysis with polydimethylsiloxane injection laryngoplasty: our experience.

Authors:  G Bergamini; M Alicandri-Ciufelli; G Molteni; D Villari; M P Luppi; E Genovese; L Presutti
Journal:  J Voice       Date:  2009-01-29       Impact factor: 2.009

Review 3.  Recurrent laryngeal nerve monitoring versus identification alone on post-thyroidectomy true vocal fold palsy: a meta-analysis.

Authors:  Thomas S Higgins; Reena Gupta; Amy S Ketcham; Robert T Sataloff; J Trad Wadsworth; John T Sinacori
Journal:  Laryngoscope       Date:  2011-05       Impact factor: 3.325

4.  American Thyroid Association Statement on Postoperative Hypoparathyroidism: Diagnosis, Prevention, and Management in Adults.

Authors:  Lisa A Orloff; Sam M Wiseman; Victor J Bernet; Thomas J Fahey; Ashok R Shaha; Maisie L Shindo; Samuel K Snyder; Brendan C Stack; John B Sunwoo; Marilene B Wang
Journal:  Thyroid       Date:  2018-06-29       Impact factor: 6.568

5.  Central compartment reoperation for recurrent/persistent differentiated thyroid cancer: patterns of recurrence, morbidity, and prediction of postoperative hypocalcemia.

Authors:  Jong-Lyel Roh; Jin-Man Kim; Chan Il Park
Journal:  Ann Surg Oncol       Date:  2010-12-08       Impact factor: 5.344

6.  Randomized clinical trial of visualization versus neuromonitoring of recurrent laryngeal nerves during thyroidectomy.

Authors:  M Barczyński; A Konturek; S Cichoń
Journal:  Br J Surg       Date:  2009-03       Impact factor: 6.939

7.  Surgical approach and outcomes for revision surgery of the central neck compartment.

Authors:  Melih Cayonu; Aydin Acar; Adil Eryilmaz; Oguzhan Oguz
Journal:  J Craniofac Surg       Date:  2014-09       Impact factor: 1.046

8.  Central lymph node dissection as a secondary procedure for papillary thyroid cancer: Is there added morbidity?

Authors:  Raul Alvarado; Mark S Sywak; Leigh Delbridge; Stan B Sidhu
Journal:  Surgery       Date:  2009-03-27       Impact factor: 3.982

9.  Algorithm for safe and effective reoperative thyroid bed surgery for recurrent/persistent papillary thyroid carcinoma.

Authors:  Tarik Y Farrag; Nishant Agrawal; Sheila Sheth; Chetan Bettegowda; Marjorie Ewertz; Matthew Kim; Ralph P Tufano
Journal:  Head Neck       Date:  2007-12       Impact factor: 3.147

10.  Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma.

Authors:  Gary L Clayman; Thomas D Shellenberger; Lawrence E Ginsberg; Beth S Edeiken; Adel K El-Naggar; Rena V Sellin; Steven G Waguespack; Dianna B Roberts; Anupam Mishra; Steven I Sherman
Journal:  Head Neck       Date:  2009-09       Impact factor: 3.147

View more
  2 in total

Review 1.  Prophylactic Central Neck Dissection in Well-differentiated Thyroid Cancer.

Authors:  Krešimir Gršić; Boris Bumber; Renata Curić Radivojević; Dinko Leović
Journal:  Acta Clin Croat       Date:  2020-06       Impact factor: 0.780

2.  Preoperative Sonographic and Clinicopathological Predictors for Solitary Lateral Neck Node Metastasis in Papillary Thyroid Carcinoma: A Retrospective Study.

Authors:  Qiong Yang; Pei Chen; Hui-Yu Hu; Hai-Long Tan; Gui-You Li; Mian Liu; Deng-Jie Ou-Yang; Rooh-Afza Khushbu; Deepak Pun; Zhi-Peng Zhang; Peng Huang; Shi Chang
Journal:  Cancer Manag Res       Date:  2020-03-12       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.